Cellectar reports Q2 2024 cash of $25.9M; pivotal WM trial shows 80% ORR, exceeding primary endpoint

Cellectar Biosciences, Inc.

2024-Q2 EPS reported -$0.86

Cash and equivalents $25.9M as of June 30, 2024, up from $9.6M at Dec 31, 2023. Net cash used in ops Q2 2024 was $14.1M.
R&D expense $8.2M (Q2 2024) vs $6.3M (Q2 2023); G&A $6.4M vs $2.0M.
CLOVER WaM study: 80% ORR, 56.4% MRR exceeded primary endpoint of 20% MRR; median prior lines of therapy was 4.
NDA filing for iopofosine I 131 in WM planned for Q4 2024; accelerated 6-month review; potential 2025 launch.
Raised $19.4M in July 2024; cash runway into Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.